Calithera Biosciences (CALA) announced the granting of stock options to two new employees, allowing them to purchase 15,200 shares at an exercise price of $5.82, the closing price on May 29, 2020. The options will vest over a four-year period, with one-fourth vesting in May 2021. This move is aimed at recruiting talent under the 2018 Inducement Plan. The press release emphasizes Calithera's focus on developing innovative cancer therapies while cautioning that forward-looking statements regarding clinical trials may not guarantee future performance.
Calithera Biosciences, Inc. (CALA) announced the granting of a non-qualified stock option to a new employee for 3,500 shares at an exercise price of $6.13, reflecting the closing price on April 30, 2020. The option vests over several years and is part of the 2018 Inducement Plan. This action aligns with Nasdaq Listing Rule 5635(c)(4) to incentivize employee recruitment. Calithera is focused on developing targeted therapies for cancer and life-threatening diseases.
Summary not available.
Calithera Biosciences (CALA) announced the presentation of an abstract for a Phase 2 study of telaglenastat, its glutaminase inhibitor, at the 2020 ASCO Virtual Annual Meeting. The KEAPSAKE study (NCT04265534) evaluates telaglenastat combined with immunotherapy and chemotherapy for patients with non-small cell lung cancer (NSCLC) harboring KEAP1/NRF2 mutations. These mutations occur in about 20% of NSCLC cases and correlate with poor treatment outcomes. The study aims to explore the efficacy of telaglenastat as a first-line treatment option, reinforcing Calithera’s commitment to innovative cancer therapies.